abstract |
The present invention relates to a composition comprising two sustained release formulations, wherein the first formulation releases the gonad stimulating hormone releasing hormone composition and the second formulation releases the estrogen composition. The composition of the present invention is applied to improved androgen deficiency treatment of prostate cancer. In the above treatments, bone density reduction, incidence and intensity of hot flushes can be maintained with minimal estrogen levels. |